The diagnosis and management of colorectal cancer (CRC) has been impacted by the
discovery and validation of a wide variety of biomarkers designed to facilitate a personalized …

Colorectal cancer (CRC) has a complex pathogenesis involving multiple sequential steps
with accumulation of genetic alterations including mutations, gene amplification, and …

Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is
heterogeneous both morphologically and molecularly. In an era of personalized medicine …

Colorectal cancer is the third most common human malignancy. Direct observation and
biopsy sampling by colonoscopy have provided unique opportunities to study the natural …

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and
women in the United States, with an estimated 153,760 new cases predicted for 2007. Since …

Colorectal cancer is a heterogeneous disease with a wide range of long-term outcomes and
responses to treatment. Recent advances in the genetic and molecular characterization of …

Progress in the treatment of colon cancer depends on the development of target-based
molecules built on an improved understanding of the molecular biology of the disease …

Colorectal cancer remains one of the most common types of cancer and leading causes of
cancer death worldwide. Although we have made steady progress in chemotherapy and …

In parallel with our growing understanding of the molecular pathways underlying colorectal
neoplasia, significant advances have been made in the treatment of colorectal cancer …

Colorectal cancer (CRC) is one of the most frequent cancers and is a leading cause of
cancer death worldwide. Treatments used for CRC may include some combination of …